Enovis™ to Acquire Leading External Fixation Product Line
May 2, 2023
ASSET ACQUISITION EXPANDS FOOT AND ANKLE OFFERINGS INTO THE EXTERNAL FIXATION MARKET
Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced a definitive agreement to acquire the SEAL external fixation product line from D.N.E., LLC. The transaction is subject to customary closing conditions and is expected to close towards the end of the second quarter of 2023.
“We are proud of the foundation we have built in the hindfoot segment with clinically differentiated products such as DynaNail, DynaNail Helix and Arsenal Ankle, and we are excited to further broaden our range of solutions with the addition of this leading external fixation line,” said Gary Justak, President and General Manager of Enovis Foot & Ankle. “The acquisition of these great products demonstrates our commitment to the Foot & Ankle space as we continue to disrupt the market and provide innovative, comprehensive solutions for surgeons and their patients.”
Enovis continues to expand its Foot & Ankle portfolio through internal development and acquisitions, including recently introduced products such as DynaClip™ Delta, DynaClip™ Quattro, Enofix™ with Constrictor Technology® and STAR® Ankle PSI.
Enovis Corporation (NYSE: ENOV) is an innovation-driven, medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services, and integrated technologies fuels active lifestyles in orthopedics and beyond. For more information about Enovis, please visit www.enovis.com.
This press release includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Enovis’ plans, goals, objectives, outlook, expectations and intentions, and other statements that are not historical or current fact. Forward-looking statements are based on Enovis’ current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Enovis’ results to differ materially from current expectations include, but are not limited to, the risks global pandemic and other factors detailed in Enovis’ reports filed with the U.S. Securities and Exchange Commission (the “SEC”), including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption “Risk Factors,” as well as the other risks discussed in Enovis’ filings with the SEC. In addition, these statements are based on assumptions that are subject to change. This press release speaks only as of the date hereof. Enovis disclaims any duty to update the information herein.
Katie Sweet, Vice President, Corporate Communications